High prevalence of off-label drug use will boost the systemic scleroderma treatment market, forecast to touch US$ 1.9 Billion by 2025 at a CAGR of 4.5%
Noida, Uttar Pradesh, India, February 22 2021 (Wiredrelease) Report Ocean Pvt Ltd –:Global Systemic scleroderma treatment Market is estimated to see healthy growth, pegged at a CAGR of ~4.5% during the forecast period 2020-2025. The supplemental approvals for existing treatment options and the rise of first-in-class therapies are presently under development that creates the growth. The change is further caused by the off-label drug use approved for its symptomatic indications, such as rheumatoid arthritis. However, the high prevalence of off-label drug use and the lack of curative therapies are underlying factors urging interest in rare disease consumption. These factors will boost the targeted biologics and small molecule combination therapies development in the coming years.
Request Sample Report at: https://reportocean.com/industry-verticals/sample-request?report_id=BWCC22
Researchers and investors are focusing on novel potential candidates developing at a rapid rate. These pipeline products vary in terms of their mechanism and type of end-use. For instance, in September 2020, Kadmon Holdings, Inc. got the Orphan Drug Designation by the US FDA for its novel drug candidate, belumosudil (KD025), intended for systemic sclerosis treatment. Belumosudil (KD025) is a Rho-associated coiled-coil kinase 2, having a dual mechanism of action for addressing both immune and fibrotic components; it is currently under phase 2 clinical trial.
Various factors responsible for the growth of systemic scleroderma treatment comprise off-label drugs for symptomatic conditions, rapidly transforming scientific literature in systemic scleroderma and first-line therapies innovations. The development towards targeted biologics and combination therapies is also enhancing the systemic scleroderma treatment demand. However, the unique drug development challenges, lack of efficient results, and recent clinical trial failures prove real-world evidence is expected to limit industry growth. For instance, in September 2020, Corbus Pharmaceuticals product Lenabasum failed to show positive phase III trials, despite promising phase II trials.
In 2019, the immunosuppressors segment led to the systemic scleroderma treatment drug type consumption. Also, considering the shortage of curative therapy for this disease, an expansive range of drug classes are prescribed to provide symptomatic release. Of these, immunosuppressants hold importance as this class contains several biologics from established players such as Roche. Biologics and small molecule immunosuppressors are a growing segment, with several pipeline drugs for systemic scleroderma focusing on this class.
North America accounts for the highest dominant share, followed by Europe and the Asia Pacific. In 2020, the region for systemic scleroderma treatment accounted for around 40% of the total. High penetration of biologics, recent innovations in the immune suppressants-based drug pipeline, and favorable reimbursement scenario will lead to the growth of the product. There are almost 20 annual cases of the diseases per million adults in the US itself. These conditions also worsen and put direct economic costs of around USD 17,365 to USD 18,396 per individual. The growth in need due to the rise in disease burden is expected to raise the systemic scleroderma treatment consumption.
Lineage Logistics, AmerisourceBergen, DHL, DB Schenker, Cardinal Logistics, McKesson, Thermo Fischer Scientific, PANASONIC HEALTHCARE CO., LTD, American Biotech Supply, Arctiko A/S, and NIPRO, among others, are some crucial players included in the research study of the global systemic scleroderma treatment market. The market players focus on a novel drug candidate rapidly, varying in action and molecular entities. Such developments based on innovations are executed to lead the industry growth and further enhance the competitive position with support from the local healthcare institutions or government.
By Drug Class Outlook (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Others)
For Purchase Enquiry: https://reportocean.com/industry-verticals/sample-request?report_id=BWCC22
This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.